Business

Cipla Signs Licence Agreement with Novartis AG; Will Manufacture Type-2 Diabetes Medicine From 2026

From January 2026, Cipla Limited will be manufacturing Galvus and Galvus combination brands that are used in the treatment of type 2 diabetes. The drug maker signed a perpetual license arrangement. Cipla in an agreement with Switzerland-based Novartis Pharma AG, the company said in an exchange filing on Monday. Up to that point, the business would keep producing and selling goods under the Galvus name.

“This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category,” it added.

The fulfilment of certain prerequisite requirements is a requirement for the agreement.

Read More: India remains top destination for Russian Urals oil

Galvus is a well-known brand in the oral diabetic treatment market and among the top brands in the Dipeptidyl Peptidase-4 (DPP4) market. With reported sales of Rs 268 crore, Galvus has the potential to considerably expand Cipla’s portfolio in the diabetes care continuum market. (IQVIA MAT February 2023).

This agreement is anticipated to strengthen Cipla’s standing as one of the leading companies in the diabetes market in India. The reflection of this was clearly seen in how shares on Cipla’s performance on Monday post the announcement. Shares of Cipla closed Monday’s trading session on the BSE 1.02% higher at Rs 901.85 a share.

The oral medication Galvus belongs to the Dipeptidyl Peptidase-4 (DPP4) class. Its reported sales of 268 crores are projected to strengthen Cipla’s position in the diabetic market, according to the statement. Decreasing prices are to be expected in the coming year.

The anti-diabetic medication Vildagliptin’s brand name and trademark rights for Vysov and Vysov M (Vildagliptin + Metformin) were purchased by Cipla in December 2019 for the Indian market. Under the trade names Vysov and Vysov M, the business had been co-marketing Vildagliptin in accordance with Novartis.

Read More: Kotak Mahindra Bank’s FPI Shareholding Crosses 25% Mark, MSCI Weightage Likely to Surge

 

 

Malika Sahni

Recent Posts

PM Modi Arrives In Chennai To Launch Metro Corridor, Other Development Projects

PM Modi arrived in Chennai to inaugurate a Metro corridor & launch highway, railway &…

38 mins ago

Delhi Police Debunks Viral Video Of ‘Sub-Inspector’ Claiming To Quit Over CJP Protest

Delhi Police called the viral Sub-Inspector resignation claim misleading and warned of legal action against…

1 hour ago

Sensex, Nifty May Face Volatility As Crude Oil & Inflation Data Loom

Crude oil prices, inflation data, rupee movements and corporate earnings are expected to influence Indian…

1 hour ago

Adani Cement Creates 70-Ft Aerial Tribute To Maa Durga Using 15,000 Cement Bags

Adani Cement has created a large-scale aerial tribute to Maa Durga using 15,000 cement bags…

2 hours ago

Delhi Police Register Over 20 FIRs Over CJP Protest Against CEC Gyanesh Kumar

Delhi Police filed 20+ FIRs over CJP protests against CEC Gyanesh Kumar; three leaders were…

2 hours ago

PM Modi, Amit Shah Pay Tribute To Jayaprakash Narayan On Birth Anniversary

Prime Minister Modi and Amit Shah paid tribute to Jayaprakash Narayan, recalling his fight for…

2 hours ago